bee venom
Animal productapproved
Approved
Mar 13, 1924
The western honey bee or European honey bee is the most common of the 7–12 species of honey bees worldwide. The genus name Apis is Latin for 'bee', and mellifera is the Latin for 'honey-bearing' or 'honey-carrying', referring to the species' production of honey. — Wikipedia
Clinical trial activity
16 trials · 16 clinical orgs · 2 marketing orgs
Phase 1
2
Phase 2
7
Phase 3
2
Phase 4
1
Earliest trial started Mar 1, 2003 (NCT00263952)
Timeline
1920s
- Mar 13, 1924
Jubilant Innovation Ltd. — Earliest FDA Approval
- Mar 13, 1924
Jubilant Innovation Ltd. — NDA Secondary Org
- Mar 13, 1924
Jubilant Innovation Ltd. — NDA Organization
1990s
- Oct 8, 1991
ALK-Abello, S.A. — NDA Secondary Org
2010s
- Jan 1, 2015
Earliest Phase 1 Sponsor(trial)
Indications
Approved for
Studied for
Mechanism of action
- bee venomImmunity, desensitized
bee venom immunity, desensitized
Approval history
- approvedMar 13, 1924
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaWestern honey bee ↗
- NCATS76013O881M ↗
- WikipediaWestern_honey_bee ↗
- WikipediaApitoxin ↗
Also known as
- bee venom
- essential bee venom
- honeybee venom
- venoms, honey bee venom
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07151313 | N/A | Sep 15, 2025 | Sinai University |
| NCT06901102 | Phase 1/Phase 2 (Phase 2) | Apr 10, 2025 | Mansoura University |
| NCT06106230 | N/A | Jan 1, 2024 | MTI University |
| NCT06374563 | N/A | Nov 9, 2022 | Badr University |
| NCT05285930 | N/A | Aug 1, 2021 | Cairo University |
| NCT05286463 | N/A | Mar 2, 2021 | Cairo University |
| NCT03753776 | Phase 3 | Jun 1, 2019 | Institut de Cancérologie de la Loire (ICLN), Institut de Cancérologie Lucien Neuwirth |
| NCT02364349 | Phase 1 | Jan 1, 2015 | Jaseng Hospital of Korean Medicine |
| NCT02101632 | N/A | Feb 1, 2014 | Silesian University of Medicine |
| NCT01922466 | Phase 2 | Jul 1, 2013 | Korea Institute of Oriental Medicine, Kyung Hee University |
| NCT01369238 | N/A | Jun 1, 2011 | Korean Pharmacoacupuncture Institute, Kyung Hee University |
| NCT01491321 | Phase 2 | Apr 1, 2011 | Kyung Hee University |
| NCT01341431 | Phase 2 | Mar 1, 2011 | University of Paris |
| NCT00949754 | Phase 2 | Oct 1, 2009 | Apimeds |
| NCT00684476 | Phase 4 | Jun 1, 2004 | Tel Aviv University |
| NCT00263952 | Phase 3 | Mar 1, 2003 | Allergopharma GmbH & Co. KG |
Showing 16 of 16 trials
Page 1 / 1
Organizations
Research & Development (16)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Kyung Hee University | Academic/Hospital | 3 | 2 | 2 | 2011 |
| Cairo University | Academic/Hospital | 2 | 2 | 1 | 2021 |
| Allergopharma GmbH & Co. KG | For profit | 1 | 1 | 1 | 2003 |
| Apimeds | For profit | 1 | 1 | 1 | 2009 |
| Badr University | Academic/Hospital | 1 | 1 | 1 | 2022 |
| Institut de Cancérologie de la Loire (ICLN) | Academic/Hospital | 1 | 1 | 1 | 2019 |
| Institut de Cancérologie Lucien Neuwirth | Academic/Hospital | 1 | 0 | 1 | 2019 |
| Jaseng Hospital of Korean Medicine | Academic/Hospital | 1 | 1 | 1 | 2015 |
| Korea Institute of Oriental Medicine | Academic/Hospital | 1 | 0 | 1 | 2013 |
| Korean Pharmacoacupuncture Institute | Academic/Hospital | 1 | 1 | 1 | 2011 |
| Mansoura University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| MTI University | Academic/Hospital | 1 | 1 | 1 | 2024 |
| Silesian University of Medicine | Academic/Hospital | 1 | 1 | 1 | 2014 |
| Sinai University | Academic/Hospital | 1 | 1 | 1 | 2025 |
| Tel Aviv University | Academic/Hospital | 1 | 1 | 1 | 2004 |
| University of Paris | Academic/Hospital | 1 | 1 | 1 | 2011 |
16 organizations
Page 1 / 1
Marketing (3)
| Organization | Org type | Relationship | Date |
|---|---|---|---|
| ALK-Abello, S.A. | For profit | NDA2 | Oct 8, 1991 |
| Jubilant Innovation Ltd. | For profit | NDA2 | Mar 13, 1924 |
| Jubilant Innovation Ltd. | For profit | NDA | Mar 13, 1924 |